References
1. Zeltins A. Construction and characterization of virus-like particles:
a review. Mol Biotechnol. 2013;53(1):92-107.
2. Liu J, Dai S, Wang M, Hu Z, Wang H, Deng F. Virus like particle-based
vaccines against emerging infectious disease viruses. Virol Sin.2016;31(4):279-287.
3. Ding X, Liu D, Booth G, Gao W, Lu Y. Virus-Like Particle Engineering:
From Rational Design to Versatile Applications. Biotechnology
Journal. 2018;13(5).
4. Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z. Virus-like particles:
potential veterinary vaccine immunogens. Research in Veterinary
Science. 2012;93(2):553-559.
5. Qi Y, Fan J, Huang W, et al. Expression and characterization of
hepatitis E virus-like particles and non-virus-like particles from
insect cells. Biotechnol Appl Biochem. 2016;63(3):362-370.
6. Jariyapong P, Xing L, van Houten NE, et al. Chimeric hepatitis E
virus-like particle as a carrier for oral-delivery. Vaccine.2013;31(2):417-424.
7. Nimgaonkar I, Ding Q, Schwartz RE, Ploss A. Hepatitis E virus:
advances and challenges. Nat Rev Gastroenterol Hepatol.2018;15(2):96-110.
8. Smith DB, Simmonds P, Izopet J, et al. Proposed reference sequences
for hepatitis E virus subtypes. J Gen Virol. 2016;97(3):537-542.
9. Yamashita T, Mori Y, Miyazaki N, et al. Biological and immunological
characteristics of hepatitis E virus-like particles based on the crystal
structure. Proc Natl Acad Sci U S A. 2009;106(31):12986-12991.
10. Guu TSY, Liu Z, Ye Q, et al. Structure of the hepatitis E virus-like
particle suggests mechanisms for virus assembly and receptor binding.Proceedings of the National Academy of Sciences.2009;106(31):12992-12997.
11. Li TC, Yamakawa Y, Suzuki K, et al. Expression and self-assembly of
empty virus-like particles of hepatitis E virus. J Virol.1997;71(10):7207-7213.
12. Li TC, Takeda N, Miyamura T, et al. Essential elements of the capsid
protein for self-assembly into empty virus-like particles of hepatitis E
virus. J Virol. 2005;79(20):12999-13006.
13. Wei M, Zhang X, Yu H, et al. Bacteria expressed hepatitis E virus
capsid proteins maintain virion-like epitopes. Vaccine.2014;32(24):2859-2865.
14. Zhang X, Wei M, Pan H, et al. Robust manufacturing and comprehensive
characterization of recombinant hepatitis E virus-like particles in
HecolinĀ®. Vaccine. 2014;32(32):4039-4050.
15. Shima R, Li TC, Sendai Y, et al. Production of hepatitis E
virus-like particles presenting multiple foreign epitopes by
co-infection of recombinant baculoviruses. Scientific Reports.2016;6(1).
16. Niikura M, Takamura S, Kim G, et al. Chimeric Recombinant Hepatitis
E Virus-like Particles as an Oral Vaccine Vehicle Presenting Foreign
Epitopes. Virology. 2002;293(2):273-280.
17. Kui X, Sun M, Xie T, et al. The Expression, Purification, and
Immunogenicity of a New Chimeric Virus-like Particle. Viral
Immunology. 2009;22(1):49-56.
18. Wang C-Y, Miyazaki N, Yamashita T, et al. Crystallization and
preliminary X-ray diffraction analysis of recombinant hepatitis E
virus-like particle. Acta Crystallographica Section F Structural
Biology and Crystallization Communications. 2008;64(4):318-322.
19. Tan M, Jiang X. Recent advancements in combination subunit vaccine
development. Human Vaccines & Immunotherapeutics.2016;13(1):180-185.
20. Deepak PR, Saravanan P, Biswal JK, et al. Generation of acid
resistant virus like particles of vaccine strains of foot-and-mouth
disease virus (FMDV). Biologicals. 2019;60:28-35.
21. Xu W, Zhang Z, Nfon C, Yang M. Genetic and antigenic relationship of
foot-and-mouth disease virus serotype O isolates with the vaccine strain
O1/BFS. Vaccine. 2018;36(26):3802-3808.
22. Yamada M, Fukai K, Morioka K, et al. Early pathogenesis of the
foot-and-mouth disease virus O/JPN/2010 in experimentally infected pigs.J Vet Med Sci. 2018;80(4):689-700.
23. Zhu Z, Yang F, He J, et al. First detection of foot-and-mouth
disease virus O/ME-SA/Ind2001 in China. Transbound Emerg Dis.2018;65(6):2027-2031.
24. Brown F. New approaches to vaccination against foot-and-mouth
disease. Vaccine. 1992;10(14):1022-1026.
25. Wang CY, Chang TY, Walfield AM, et al. Synthetic peptide-based
vaccine and diagnostic system for effective control of FMD.Biologicals. 2001;29(3-4):221-228.
26. Cao Y, Lu Z, Li D, et al. Evaluation of cross-protection against
three topotypes of serotype O foot-and-mouth disease virus in pigs
vaccinated with multi-epitope protein vaccine incorporated with
poly(I:C). Vet Microbiol. 2014;168(2-4):294-301.
27. Cao Y, Lu Z, Li Y, et al. Poly(I:C) combined with multi-epitope
protein vaccine completely protects against virulent foot-and-mouth
disease virus challenge in pigs. Antiviral Research.2013;97(2):145-153.
28. Briand JP, Benkirane N, Guichard G, et al. A retro-inverso peptide
corresponding to the GH loop of foot-and-mouth disease virus elicits
high levels of long-lasting protective neutralizing antibodies.Proc Natl Acad Sci U S A. 1997;94(23):12545-12550.
29. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2
web portal for protein modeling, prediction and analysis. Nat
Protoc. 2015;10(6):845-858.
30. Heo L, Park H, Seok C. GalaxyRefine: Protein structure refinement
driven by side-chain repacking. Nucleic Acids Res. 2013;41(Web
Server issue):W384-388.
31. Wei W, Behloul N, Baha S, Liu Z, Aslam MS, Meng J. Dimerization: a
structural feature for the protection of hepatitis E virus capsid
protein against trypsinization. Sci Rep. 2018;8(1):1738.
32. Baek M, Park T, Heo L, Park C, Seok C. GalaxyHomomer: a web server
for protein homo-oligomer structure prediction from a monomer sequence
or structure. Nucleic Acids Res. 2017;45(W1):W320-W324.
33. Zhai L, Dai X, Meng J. Hepatitis E virus genotyping based on
full-length genome and partial genomic regions. Virus Res.2006;120(1-2):57-69.
34. Zhang H, Dai X, Shan X, Meng J. Characterization of antigenic
epitopes of the ORF2 protein from hepatitis E virus genotype 4.Virus Res. 2009;142(1-2):140-143.
35. Ponomarenko J, Bui H-H, Li W, et al. ElliPro: a new structure-based
tool for the prediction of antibody epitopes. BMC Bioinformatics.2008;9(1).
36. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving
bioscience research reporting: the ARRIVE guidelines for reporting
animal research. PLoS Biol. 2010;8(6):e1000412.
37. Liu Z, Behloul N, Baha S, Wei W, Shi R, Meng J. Design and
immunogenicity analysis of the combined vaccine against zoonotic
hepatitis E and foot-and-mouth disease. Vaccine.2019;37(46):6922-6930.
38. Xing L, Li TC, Mayazaki N, et al. Structure of hepatitis E
virion-sized particle reveals an RNA-dependent viral assembly pathway.J Biol Chem. 2010;285(43):33175-33183.
39. Chen R, Neill JD, Estes MK, Prasad BV. X-ray structure of a native
calicivirus: structural insights into antigenic diversity and host
specificity. Proc Natl Acad Sci U S A. 2006;103(21):8048-8053.
40. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK.
X-ray crystallographic structure of the Norwalk virus capsid.Science. 1999;286(5438):287-290.
41. Mori Y, Matsuura Y. Structure of hepatitis E viral particle.Virus Research. 2011;161(1):59-64.
42. Grgacic EVL, Anderson DA. Virus-like particles: Passport to immune
recognition. Methods. 2006;40(1):60-65.
43. Li S, Zhang J, Xia N. Lessons from hepatitis E vaccine design.Curr Opin Virol. 2015;11:130-136.
44. Naskalska A, Pyrc K. Virus Like Particles as Immunogens and
Universal Nanocarriers. Pol J Microbiol. 2015;64(1):3-13.